Special Issue

The Study of Molecular Pathogenesis and Therapeutic Strategies of Pancreatic Cancer

Message from the Guest Editor

I am pleased to invite you to contribute to the Special Issue entitled “The Study of Molecular Pathogenesis and Therapeutic Strategies of Pancreatic Cancer”. Pancreatic cancer is an aggressive form of cancer characterised by poor prognosis and survival rate. Despite rapid progress in this field, and the fact that the core genetic mutations associated with pancreatic cancer are well known, their role in pancreatic cancer pathogenesis and progression is yet to be explored. Henceforth, delineating the heterogeneous molecular pathology of this cancer will facilitate the identification of new molecular targets for personalised therapeutic options. This Special Issue aims to discuss recent advancements in our understanding of new molecular targets, multifocal neoplasia associated with precancerous lesions, dysregulation/upregulation of cell signalling networks, pathophysiology of the complex tumour microenvironment and innovative therapeutic intervention in pancreatic cancer. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: original research articles and reviews.

Guest Editor

Prof. Dr. Marco Falasca

Department of Medicine and Surgery, University of Parma, Via Volturno, 39, 43125 Parma, Italy

Deadline for manuscript submissions

closed (31 July 2023)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/131967

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)